NCT00526071View on ClinicalTrials.gov

Open-label Long-term Safety Study of AT1001 (Migalastat Hydrochloride) in Participants With Fabry Disease Who Have Completed a Previous AT1001 Study

PHASE2TerminatedINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

September 17, 2007

Primary Completion Date

September 8, 2012

Study Completion Date

September 8, 2012

Conditions
Fabry Disease
Interventions
DRUG

migalastat HCl

Trial Locations (8)

10016

New York

30033

Decatur

78226

Dallas

Unknown

Parkville

Porto Alegre

Garches

London

Salford

Sponsors
All Listed Sponsors
lead

Amicus Therapeutics

INDUSTRY